Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHI-MING TU and CHRISTOPHER J LOGOTHETIS.
SHI-MING TU
Connection Strength
2.068
CHRISTOPHER J LOGOTHETIS
  1. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51.
    View in: PubMed
    Score: 0.380
  2. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24.
    View in: PubMed
    Score: 0.355
  3. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10.
    View in: PubMed
    Score: 0.278
  4. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41.
    View in: PubMed
    Score: 0.200
  5. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201.
    View in: PubMed
    Score: 0.165
  6. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996 Nov-Dec; 2(6):191-7.
    View in: PubMed
    Score: 0.149
  7. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995 Nov; 154(5):1719-22.
    View in: PubMed
    Score: 0.139
  8. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012 Aug 07; 107(4):646-51.
    View in: PubMed
    Score: 0.111
  9. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
    View in: PubMed
    Score: 0.083
  10. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 01; 80(11):2128-32.
    View in: PubMed
    Score: 0.040
  11. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6.
    View in: PubMed
    Score: 0.040
  12. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500.
    View in: PubMed
    Score: 0.040
  13. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995 Sep; 13(9):2272-7.
    View in: PubMed
    Score: 0.034
  14. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012 Oct 23; 107(9):1547-53.
    View in: PubMed
    Score: 0.028
  15. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
    View in: PubMed
    Score: 0.014
  16. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 01; 89(3):615-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.